DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3 STUDIES

被引：1
|
作者：
Stopeck, A. T. [1 ]
Richardson, G. [2 ]
Siena, S. [3 ]
Lipton, A. [4 ]
Brown, J. [5 ]
Fizazi, K. [6 ]
Henry, D. [7 ]
Saad, F. [8 ]
Ke, C. [9 ]
Braun, A. [9 ]
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] Cabrini Hosp, Malvern, Vic, Australia
[3] Osped Niguarda Ca Granda, Milan, Italy
[4] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[5] Canc Res, UK Clin Ctr, Leeds, W Yorkshire, England
[6] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[7] Joan Karnell Canc Ctr, Philadelphia, PA USA
[8] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/j.ejca.2012.02.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [31] ZOLEDRONIC ACID IS COST EFFECTIVE FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES IN FRANCE AND GERMANY
    Meijboom, Marjan
    Botteman, Marc F.
    Kaura, Satyin
    JOURNAL OF UROLOGY, 2009, 181 (04): : 295 - 295
  • [32] ECONOMIC EVALUATION OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) IN THE PREVENTION OF SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH PROSTATE CANCER WITH BONE METASTASIS (BM) IN MEXICO
    Arocho, R.
    Rivera Hurtado, R.
    Carlos, F.
    VALUE IN HEALTH, 2013, 16 (03) : A139 - A140
  • [33] MODELING THE LIFETIME EFFECTIVENESS OF DENOSUMAB AND ZOLEDRONIC ACID (ZA) IN THE PREVENTION OF SKELETAL RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS
    Danese, M. D.
    Bracco, A.
    Macarios, D.
    Chung, K.
    Barlev, A.
    Halperin, M.
    Lothgren, M.
    VALUE IN HEALTH, 2011, 14 (03) : A179 - A179
  • [34] An Italian survey on the use of denosumab for the management of skeletal-related events in patients with bone metastases
    Berardi, R.
    Berruti, A.
    Brogelli, L.
    Zucali, P. A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (13) : 4659 - 4665
  • [35] Symptomatic skeletal events (SSEs) versus skeletal- related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid
    von Moos, R.
    Costa, L. A. M.
    Scagliotti, G.
    Sleeboom, H.
    Goldwasser, F.
    Hirsh, V.
    Spencer, A.
    Radcliffe, H-S.
    Niepel, D.
    Henry, D. H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] ZOLEDRONIC ACID IS COST EFFECTIVE FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM RENAL CELL CARCINOMA: A FRENCH EXPLORATORY ANALYSIS
    Botteman, Marc F.
    Stephens, Jennifer M.
    Foley, Isaac
    Kaura, Satyin
    JOURNAL OF UROLOGY, 2009, 181 (04): : 500 - 500
  • [37] IMPACT ON HOSPITALIZATION DERIVED FROM THE USE OF DENOSUMAB FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO BREAST CANCER IN GERMANY
    Diel, I
    Ikenberg, R.
    Cristino, J.
    Gatta, F.
    Qian, Y.
    Arellano, J.
    VALUE IN HEALTH, 2014, 17 (07) : A644 - A645
  • [38] Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
    Boysen, A. K.
    Andersen, I. T.
    Acquavella, J.
    Seesaghur, A. M.
    Hernandez, R. K.
    Ehrenstein, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 731 - 731
  • [39] Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland
    Lothgren, Mickael
    Ribnicsek, Erna
    Schmidt, Louise
    Habacher, Wolfgang
    Lundkvist, Jonas
    Pfeil, Alena M.
    Biteeva, Irina
    Vrouchou, Polina
    Bracco, Andrea
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2013, 20 (04): : 227 - 231
  • [40] Cost-effectiveness of denosumab versus zoledronic acid in patients with bone metastases from solid tumours in Spain
    Duran, I.
    Segui, M. A.
    Isla, D.
    Oyagueez, I.
    Roldan, C.
    Casado, M. A.
    Lothgren, M.
    Hechmati, G.
    Gutierrez, L.
    Gasquet, J. A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S334 - S334
12345